| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Geraniin has an IC50 value of 43 μM for blocking TNF-α release[1]. Throughout this time, geraniin has been utilized as a botanical remedy for a range of conditions, such as antihyperglycemic, anticancer, and anti-inflammatory effects. OVCAR3 and SKOV3 cell viability was dramatically decreased by geraniin in a concentration-dependent way. Geranol treatment resulted in IC50 values of 34.5±2.8 μM in OVCAR3 cells and 23.6±1.9 μM in SKOV3 cells. However, utilizing up to the maximum dose (80 μM) of geranol, treatment with 10 and 40 μM for 48 hours led to a substantial increase in cell fluorescence compared with normal versus control OVCAR3 cells (3.9 ± 1.1%). 22.6±1.4%) and 16.8±1.2%. Comparable outcomes were noted in SKOV3 cells [2].
|
|---|---|
| ln Vivo |
In comparison to acid treatment, geranol treatment postponed the formation of tumors, decreasing the percentage of tumor-bearing mice from 80.0% to 40.0% and the average number of tumors per mouse at week 20 from 3.8 to 1.1. Additionally, a schematic diagram demonstrated how geranin (50 mg/kg/d or 100 mg/kg/d) inhibited the activities of glutamic acid pyruvate aminotransferase, glutamic acid oxalopyruvate aminotransferase, starch esters, and total starch when treated with peroxidized oil[1].
|
| References |
|
| Additional Infomation |
Geraniin is a tannin.
Geraniin has been reported in Euphorbia prostrata, Phyllanthus sellowianus, and other organisms with data available. |
| Molecular Formula |
C41H28O27
|
|---|---|
| Molecular Weight |
952.6448
|
| Exact Mass |
952.081
|
| CAS # |
60976-49-0
|
| PubChem CID |
3001497
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Index of Refraction |
1.948
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
68
|
| Complexity |
2080
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@@H]7C(=CC(=O)[C@@](C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O
|
| InChi Key |
JQQBXPCJFAKSPG-SVYIMCMUSA-N
|
| InChi Code |
InChI=1S/C41H28O27/c42-13-1-8(2-14(43)24(13)48)34(54)67-39-33-32-30(64-38(58)12-6-19(47)41(61)40(59,60)23(12)22-11(37(57)66-33)5-17(46)27(51)31(22)68-41)18(63-39)7-62-35(55)9-3-15(44)25(49)28(52)20(9)21-10(36(56)65-32)4-16(45)26(50)29(21)53/h1-6,18,23,30,32-33,39,42-46,48-53,59-61H,7H2/t18-,23+,30-,32+,33-,39+,41+/m1/s1
|
| Chemical Name |
[(1R,7R,8S,26R,28S,29R,38R)-1,13,14,15,18,19,20,34,35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5-trihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~104.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0497 mL | 5.2486 mL | 10.4971 mL | |
| 5 mM | 0.2099 mL | 1.0497 mL | 2.0994 mL | |
| 10 mM | 0.1050 mL | 0.5249 mL | 1.0497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
